Unaudited Financial Statements

for the Year Ended 31st March 2017

for

European Platform For
Photodynamic Medicine
European Platform For
Photodynamic Medicine (Registered number: 06289572)

Contents of the Financial Statements
for the year ended 31st March 2017

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Company Information</td>
<td>1</td>
</tr>
<tr>
<td>Balance Sheet</td>
<td>2</td>
</tr>
<tr>
<td>Notes to the Financial Statements</td>
<td>3</td>
</tr>
<tr>
<td>Chartered Accountants' Report</td>
<td>4</td>
</tr>
</tbody>
</table>
European Platform For
Photodynamic Medicine

Company Information
for the year ended 31st March 2017

DIRECTORS: C Hopper
            Professor K. Moghissi BSc MD FRCS
            Professor H Walt
            Dr E Allan

REGISTERED OFFICE: Princes House
                   Wright Street
                   Hull
                   HU2 8HX

REGISTERED NUMBER: 06289572 (England and Wales)

ACCOUNTANTS: ebaSadofskys
              Chartered Accountants
              Princes House
              Wright Street
              Hull
              East Yorkshire
              HU2 8HX
European Platform For  
Photodynamic Medicine (Registered number: 06289572)  

Balance Sheet  
31st March 2017

<table>
<thead>
<tr>
<th>Notes</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€</td>
<td>€</td>
</tr>
<tr>
<td>CURRENT ASSETS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash at bank</td>
<td>6,344</td>
<td>7,799</td>
</tr>
<tr>
<td>CREDITORS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amounts falling due within one year</td>
<td>623</td>
<td>654</td>
</tr>
<tr>
<td>NET CURRENT ASSETS</td>
<td>5,721</td>
<td>7,145</td>
</tr>
<tr>
<td>TOTAL ASSETS LESS CURRENT LIABILITIES</td>
<td>5,721</td>
<td>7,145</td>
</tr>
<tr>
<td>RESERVES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income and expenditure account</td>
<td>5,721</td>
<td>7,145</td>
</tr>
</tbody>
</table>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2017.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors on 5th December 2017 and were signed on its behalf by:

Professor K Moghissi BSc MD FRCS - Director

The notes form part of these financial statements
1. **STATUTORY INFORMATION**

European Platform For Photodynamic Medicine is a private company, limited by guarantee, registered in England and Wales. The company’s registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Euro (€).

2. **ACCOUNTING POLICIES**

   **Basis of preparing the financial statements**
   These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

   **Turnover**
   Turnover represents subscriptions and donations received.

3. **CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Directors’ current accounts</td>
<td>124</td>
<td>124</td>
</tr>
<tr>
<td>Accrued expenses</td>
<td>499</td>
<td>530</td>
</tr>
<tr>
<td></td>
<td>623</td>
<td>654</td>
</tr>
</tbody>
</table>

4. **FIRST YEAR ADOPTION**

   The company has adopted FRS102 Section 1a for the first time during the year ended 31st March 2017 and consequently the transition date is 1st April 2015.

   The effect of transition from previous UK GAAP to FRS102 is outlined below:

   1. There were no consequential changes in accounting policies as a result of the transition.
   2. There were no adjustments to previously reported equity shareholders’ funds at the date of transition.
   3. There were no adjustments to previously reported profit or losses in the comparative period.
Chartered Accountants’ Report to the Board of Directors
on the Unaudited Financial Statements of
European Platform For
Photodynamic Medicine

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of European Platform For Photodynamic Medicine for the year ended 31st March 2017 which comprise the Statement of Income and Retained Earnings, Balance Sheet and the related notes from the company’s accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW’s regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of European Platform For Photodynamic Medicine, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of European Platform For Photodynamic Medicine and state those matters that we have agreed to state to the Board of Directors of European Platform For Photodynamic Medicine, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than European Platform For Photodynamic Medicine Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that European Platform For Photodynamic Medicine has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of European Platform For Photodynamic Medicine. You consider that European Platform For Photodynamic Medicine is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of European Platform For Photodynamic Medicine. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

cbSadofskys
Chartered Accountants
Princes House
Wright Street
Hull
East Yorkshire
HU2 8HX

7th December 2017

This page does not form part of the statutory financial statements
This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.